Immunotherapy
a review on the new horizons of cancer-fighting
DOI:
https://doi.org/10.11606/issn.1679-9836.v99i2p148-155Keywords:
Immunotherapy, adoptive, Immunotherapy, Neoplasms/therapy, T-LymphocytesAbstract
Introduction: Immunotherapy is progressing to become an expressive tool in the fight against cancer, from manipulating the immune system of patients to eliminate tumors. Many institutions have invested in research in the field, since the immunotherapeutic approaches have advantages over conventional therapies, in addition to presenting potential for hitherto intractable cancers. Objective: To define some mechanisms based on immunotherapy, in addition to citing their classes and in which types of cancer these therapies have been used. Method: This is a literature review of the selection of articles from the last 10 years in the PubMed database with the keywords “Immunotherapy, Adoptive” combined with the term “Lymphocytes, Tumor-Infiltrating” and “Immunotherapy, Adoptive”, combined with “Neoplasms.” Results: The term immunotherapy represents a vast class of treatments based on the Immunity Cycle of Cancer Checkpoint. Inhibitors, for example, block immunosuppressive mechanisms performed by the tumor. In another instance is adoptive cell therapy, which consists of extracting and training T-lymphocytes from the patients themselves to identify and combat specific antigens of the tumor tissue. Also noteworthy are the vaccines, which use attenuated and genetically modified tumor cells to stimulate the immune response. These therapies are being studied in several types of cancers, showing encouraging results in melanomas, breast cancers, glioblastomas, hematologic cancers, like the metastatic myeloma, among others. In addition, the combination of immunotherapeutic techniques with conventional therapies is also a promising alternative. However, barriers to consolidating a more efficient and lower-cost production method still limit the mass use of some of these therapies. Conclusion: Many immunotherapeutic approaches are still experimental and their comprehensive application is still uncertain, however, the results obtained by the clinical studies demonstrate the exciting perspective for this new horizon in the fight against cancer.
Downloads
References
Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18(12):e731-e741. doi: 10.1016/S1470-2045(17)30607-1.
Noonan KA, Huff CA, Davis J, Lemas MV, Fiorino S, Bitzan J, Ferguson A, Emerling A, Luznik L, Matsui W, Powell J, Fuchs E, Rosner GL, Epstein C, Rudraraju L, Ambinder RF, Jones RJ, Pardoll D, Borrello I. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015 20;7(288):288ra78. doi: 10.1126/scitranslmed.aaa7014.
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135-46. doi: 10.1038/nrc3670.
McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue Sarcomas. Iowa Orthop J. 2006;26:154-8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1888599/.
Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991;(262):3-11. Available from: https://bit.ly/36OyFHs.
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.
Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61-73. doi: 10.1016/j.immuni.2013.07.005.
Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123(17):2625-35. doi: 10.1182/blood-2013-11-492231.
Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 201724;10(1):94. doi: 10.1186/s13045-017-0453-8.
Shi T, Ma Y, Yu L, Jiang J, Shen S, Hou Y, Wang T. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints. Int J Mol Sci. 2018;19(5). pii: E1389. doi: 10.3390/ijms19051389.
Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer. 2018;9(10):1773-1781. doi: 10.7150/jca.24577. eCollection 2018.
Li H, Zhao Y. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. Protein Cell. 2017;8(8):573-89. doi: 10.1007/s13238-017-0411-9.
Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D’Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016;375(26):2561-9. doi: 10.1056/NEJMoa1610497.
Dietrich PY, Dutoit V, Walker PR. Immunotherapy for glioma: from illusion to realistic prospects? Am Soc Clin Oncol Educ Book. 2014:51-9. doi: 10.14694/EdBook_AM.2014.34.51.
Baskar S, Muthusamy N. Antibody-based therapeutics for the treatment of human B cell malignancies. Curr Allergy Asthma Rep. 2013;13(1):33-43. doi:10.1007/s11882-012-0327-7.
Santoiemma PP, Powell DJ Jr. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015;16(6):807-20. doi: 10.1080/15384047.2015.1040960.
Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep. 2012;14(5):468-74. doi: 10.1007/s11912-012-0257-5.
Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16(9):2646-55. doi: 10.1158/1078-0432.CCR-10-0041.
Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233-40. doi: 10.1016/j.coi.2009.03.002.
Shore ND. Avanços no entendimento da imunoterapia do câncer. BJU Int. 2015;116:321-9.
Levy EM, Roberti MP; Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol. 2011; 2011:676198. doi: 10.1155/2011/676198.
Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148(7):1383-91.e6. doi: 10.1053/j.gastro.2015.02.055.
Hu J, Hu J, Liu X, Hu C, Li M, Han W. Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: a meta-analysis. Medicine (Baltimore). 2017;96(42):e8310. doi: 10.1097/MD.0000000000008310.
Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007;5(1):67. doi: 10.1186/1479-5876-5-67.
Lin Y, Okada H. Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther. 2016;16(10):1265-75. doi: 10.1080/14712598.2016.1214266.
